12 studies found for:    alzheimer's and long island jewish
Show Display Options
Rank Status Study
1 Terminated A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Bapineuzumab
2 Active, not recruiting Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb);   Drug: Placebo
3 Terminated
Has Results
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001+ QS21 (3mcg);   Biological: ACC-001 (10 mcg) + QS-21;   Biological: ACC-001+QS-21 (30mcg)
4 Active, not recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
5 Enrolling by invitation Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Conditions: Alzheimer's Disease;   Behavioral Variant Frontotemporal Dementia
Intervention: Drug: TRx0237
6 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
7 Completed Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
Condition: Alzheimer's Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Placebo Control;   Drug: Bapineuzumab 1.0 m/kg
8 Recruiting An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease
Condition: Alzheimer´s Disease
Interventions: Drug: LY3314814;   Drug: Placebo
9 Unknown  Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease
Condition: Alzheimer Disease
Intervention: Drug: 3APS
10 Recruiting Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
Condition: Alzheimer's Disease
Interventions: Drug: Piromelatine;   Drug: Placebo
11 Completed Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 200 mg/day;   Drug: Placebo
12 Completed Memory Impairment Study (Mild Cognitive Impairment Study)
Condition: Alzheimer Disease
Interventions: Drug: Donepezil;   Drug: Vitamin E

Indicates status has not been verified in more than two years